Why TG Therapeutics (TGTX) Stock Is Down Today

2026-11-09

Investivoq PriceTracker

TG Therapeutics (TGTX) is down 4.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is a sell-the-news reaction to TG Therapeutics’ third-quarter results. The company posted strong BRIUMVI sales and raised full-year revenue guidance, but investors may have been hoping for an even bigger upside surprise or a nearer-term catalyst beyond the existing launch and pipeline timeline.

Details:

TG Therapeutics reported third-quarter 2026 total global revenue of about $260 million, including roughly $233 million in U.S. net product revenue from BRIUMVI.

The company lifted its 2026 outlook to about $1 billion in total global revenue and roughly $915 million to $920 million in U.S. BRIUMVI net product revenue.

Management pointed to future catalysts such as Phase 3 subcutaneous BRIUMVI data around late 2026 or early 2027 and a potential simplified IV initiation launch in mid-2027, which may have left some traders wanting something more immediate.

TG Therapeutics also disclosed $100 million of third-quarter share repurchases, suggesting capital returns were not enough to offset profit-taking after a widely anticipated strong quarter.

Sources:

TG Therapeutics, Stock Analysis, Yahoo Finance

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$TGTX Insider Trading Activity

$TGTX insiders have traded $TGTX stock on the open market 1 times in the past 6 months. Of those trades, 0 have been purchases and 1 have been sales.

Here’s a breakdown of recent trading of $TGTX stock by insiders over the last 6 months:

LAURENCE N CHARNEY sold 5,000 shares for an estimated $274,800

To track insider transactions, check out Investivoq's insider trading dashboard. You can access data on insider stock transactions through the Investivoq API insider transaction endpoint.

$TGTX Hedge Fund Activity

We have seen 226 institutional investors add shares of $TGTX stock to their portfolio, and 174 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

D. E. SHAW & CO., INC. added 2,700,463 shares (+385.6%) to their portfolio in Q2 2026, for an estimated $148,363,437
PRICE T ROWE ASSOCIATES INC /MD/ added 2,134,922 shares (+337.4%) to their portfolio in Q2 2026, for an estimated $117,292,614
BARCLAYS PLC added 1,465,946 shares (+153.0%) to their portfolio in Q3 2026, for an estimated $81,770,467
SIXTH STREET PARTNERS MANAGEMENT COMPANY, L.P. added 1,313,103 shares (+inf%) to their portfolio in Q2 2026, for an estimated $72,141,878
SOLEUS CAPITAL MANAGEMENT, L.P. removed 1,101,424 shares (-27.3%) from their portfolio in Q2 2026, for an estimated $60,512,234
TWO SIGMA INVESTMENTS, LP added 926,659 shares (+60.1%) to their portfolio in Q2 2026, for an estimated $50,910,645
MAN GROUP PLC removed 824,261 shares (-86.2%) from their portfolio in Q2 2026, for an estimated $45,284,899

To track hedge funds' stock portfolios, check out Investivoq's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Investivoq API 13F endpoint.

$TGTX Price Targets

Multiple analysts have issued price targets for $TGTX recently. We have seen 2 analysts offer price targets for $TGTX in the last 6 months, with a median target of $45.0.

Here are some recent targets:

Alec Stranahan from B of A Securities set a target price of $20.0 on 07/07/2026
Emily Bodnar from HC Wainwright & Co. set a target price of $70.0 on 07/06/2026

This article is not financial advice. See Investivoq's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.